First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent

Cancer Treatment Reviews

Volumn 34, Issue SUPPL. 2, 2008, Pages

  Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibodies, monoclonal; Antineoplastic combined chemotherapy protocols; Colorectal neoplasms

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER SIZE; CANCER STAGING; CASE REPORT; COLON RESECTION; COLONOSCOPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 57649225434     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(08)70002-1     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts & Figures 2008 (2008), American Cancer Society, Atlanta. Available at: http://www.cancer.org
2. Adam R. Current surgical strategies for the treatment of colorectal cancer liver metastases. EJC Suppl 2 (2004) 21-26
3. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
4. Pawlik T.M., Schulick R.D., and Choti M.A. Expanding criteria for resectability of colorectal liver metastases. Oncologist 13 (2008) 51-64
5. Wicherts D.A., de Haas R.J., and Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 33 Suppl 2 (2007) S42-S51
6. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004) 644-657
7. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
8. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
9. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005) 4866-4875
10. Folprecht G., Grothey A., Alberts S., Raab H.R., and Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
11. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15 (2004) 933-939
12. Alberts S.R., Horvath W.L., Sternfeld W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23 (2005) 9243-9249
13. Zelek L., Bugat R., Cherqui D., et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14 (2003) 1537-1542
14. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
15. Barone C., Nuzzo G., Cassano A., et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97 (2007) 1035-1039
16. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676
17. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
18. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
19. Fuchs C.S., and Marshall J. Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C Study. J Clin Oncol 26 (2008) 689-690
20. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7 (2007) 91
21. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer(MCRC). American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, abstract 238.
22. Moosmann N., and Heinemann V. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer 7 (2008) 110-117
23. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
24. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 352 (2005) 476-487
25. Van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Slides presented at ASCO 2007 Annual Meeting; Chicago, Illinois, June 15, 2007. Abstract 4000.
26. Taieb J., Puig P.L., and Bedenne L. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther 8 (2008) 183-189
27. Tol J., Koopman M., Rodenburg C.J., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19 (2008) 734-738
28. Punt C.J., Tol J., Rodenburg C.J., et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26 Suppl (2008 May 20) abstract LBA4011.
29. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
30. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
31. Bokemeyer C., Bondarenko J., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26 Suppl (2008) abstract 4000.
32. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26 Suppl (2008) abstract 2.
33. De Roock W., Piessevaux H., De S.J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 (2008) 508-515
34. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
35. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 (2007) 1166-1169
36. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
37. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206 (2008) 96-106
38. Bilchik A.J., Poston G., Curley S.A., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23 (2005) 9073-9078
39. August D.A., Serrano D., and Poplin E. "Spontaneous", delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 97 (2008) 180-185
40. Hurwitz H., and Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33 5 Suppl 10 (2006) S26-S34
41. Asmis T.R., Chung K.Y., Teitcher J.B., Kelsen D.P., and Shah M.A. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26 (2008) 95-96
42. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
43. Morris-Stiff G., Tan Y.M., and Vauthey J.N. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34 (2008) 609-614
44. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
45. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061